Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Study [IMPRES]), among pulmonary arterial hypertension (PAH) patients inadequately responsive to 2 to 3 PAH-specific therapies. METHODS: The long-term (up to 204 weeks) safety and efficacy of imatinib in this open-label extension study were reviewed until early study termination on April 16, 2014. Of 202 IMPRES-enrolled patients, 66 imatinib and 78 placebo recipients entered the extension. RESULTS: Overall, 93.8% (135 of 144) of patients discontinued the extension study; administrative issues (i.e., sponsor termination; 32.6%) and adverse events (31.3%) were the primary reasons for discontinuation. Nine patients completed the extension study before it was terminated. Serious and unexpected adverse events were frequent. These included 6 subdural hematomas in the extension study and 17 deaths during or within 30 days of study end. Although the patients who tolerated imatinib and remained in the extension for a longer duration did experience an improvement in functional class and walk distance, most discontinued the drug and the study. CONCLUSIONS: Severe adverse events, significant side effects, and a high discontinuation rate limit the utility of imatinib in the treatment of PAH. These risks outweigh any possible improvements in hemodynamics and walk distance seen in those patients able to remain on drug. The off-label use of this compound in PAH is discouraged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Self-citation
Cited by
Rieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0829-5 · Cited by 59
“Thus, TKI-inhibtion appears to be beneficial and particularly nebulised imatinib might prevent systemic side effect [130].”
BackgroundA systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension
Anand, V., Garg, S., Duval, S., & Thenappan, T. (2016) · Pulmonary Circulation · doi:10.1086/687304 · Cited by 25
Clonal Expansion in Cardiovascular Pathology
Lin, A., Brittan, M., Baker, A. H., Dimmeler, S., Fisher, E. A., Sluimer, J. C., & Misra, A. (2024) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.04.008 · Cited by 13
Metadata
- Authors
- Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H.-J., Frantz, R. P., Fukumoto, Y., Galié, N., Hassoun, P. M., Klose, H., Matsubara, H., Morrell, N. W., Peacock, A. J., Pfeifer, M., Simonneau, G., Tapson, V. F., Torres, F., Dario Vizza, C., Lawrence, D., Yang, W., Felser, J. M., Quinn, D. A., & Ghofrani, H.-A.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 34
- Issue
- 11
- Pages
- 1366-1375
- ISSN
- 1053-2498 (ISSN-L)
- OpenAlex
- W1929000169
- Cited by
- 148
- References
- 3
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1016/j.healun.2015.05.025
- The paper
- Frost, A. E., Barst, R. J., Hoeper, M. M., Chang, H.-J., Frantz, R. P., Fukumoto, Y., Galié, N., Hassoun, P. M., Klose, H., Matsubara, H., Morrell, N. W., Peacock, A. J., Pfeifer, M., Simonneau, G., Tapson, V. F., Torres, F., Dario Vizza, C., Lawrence, D., Yang, W., . . . Ghofrani, H.-A. (2015). Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2015.05.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.